替雷利珠单抗可能诱发免疫相关不良事件，尤其是皮肤不良事件。早期发现并及时干预皮肤不良事件对于改善患者的生活质量和减少治疗方案的中断至关重要。本研究旨在明确替雷利珠单抗皮肤不良反应的临床特征，为其临床合理使用提供参考。从相关数据库收集替雷利珠单抗引起皮肤不良反应的病例报告（截至2023年3月31日）。记录并描述性分析患者的年龄、性别、原发病、用药情况、不良皮肤状况的发生、治疗和结果。共纳入13例患者，其中男性6例，女性7例，年龄55-79岁，年龄55-79岁。中位年龄为 75 岁，平均年龄为 70.92±8.84 岁。没有患者的原发病为肺癌，2例为宫颈癌，尿路上皮癌和鳞状细胞癌各1例。从开始用药到出现皮肤不良反应的时间为7至177天。 13例患者中，10例经停药或对症治疗后病情好转。 2 例患者死亡（1 例死于疾病进展和多器官功能衰竭，1 例死于急性冠状动脉综合征），1 例患者皮肤不良反应未经治疗持续存在。替雷利珠单抗相关的皮肤不良反应大多发生在治疗数天至数月后。在临床实践中应加强评估和监测。应更多关注红斑和皮疹，这可能是严重皮肤不良反应的迹象。早期发现和干预可以确保药物的安全使用，并为患者提供更大的临床获益。

Tislelizumab may induce immune-related adverse events, especially adverse skin events. Early detection and timely intervention of cutaneous adverse events are crucial to improve patients' quality of life and reduce the disruption of therapeutic regimens. This study aimed to determine the clinical characteristics of cutaneous adverse reactions to tislelizumab and offer a reference for its rational clinical use.Case reports of cutaneous adverse reactions induced by tislelizumab were collected from the relevant databases (up to 31 March 2023). Patient age, sex, primary disease, medication use, occurrence of adverse skin conditions, treatment, and outcomes were recorded and descriptively analysed.A total of 13 patients were enrolled, including six males and seven females, aged 55-79 years, with a median age of 75 years and a mean age of 70.92 ± 8.84 years. The original disease was lung carcinoma in none patients, cervical carcinoma in two, and urothelial carcinoma and squamous cell carcinoma in one each. The time from the initiation of medication use to the occurrence of cutaneous adverse reactions ranged from 7 to 177 days. Among the 13 patients, 10 showed improvement after drug withdrawal or symptomatic treatment. Two patients died (one died of disease progression and multiorgan failure, one died of acute coronary syndrome), and one patient's adverse skin reactions persisted without treatment.Tislelizumab-related cutaneous adverse reactions mostly occur after several days to months of treatment. In clinical practice, evaluation and monitoring should be strengthened. More attention should be paid to erythema and rashes, which may be signs of serious adverse skin reactions. Early detection and intervention can ensure the safe use of drugs and provide greater clinical benefits to patients.